Proacta Raises $35 Million

Proacta Inc., a San Diego-based developer of cancer drugs that target physiological attributes of solid tumors, has raised $35 million in Series B funding. Clarus Ventures led the deal, and was joined by Delphi Ventures and return backers Alta Partners, GBS Venture Partners, New Zealand Venture Investment Fund, No 8 Ventures, Endeavour iCap, Genentech and Roche. www.proactatherapeutics.com